20101299: Study to Evaluate the Effect of AMG 747 on Schizophrenia Negative Symptoms

PHASE2TerminatedINTERVENTIONAL
Enrollment

121

Participants

Timeline

Start Date

May 31, 2012

Primary Completion Date

June 30, 2013

Study Completion Date

June 30, 2013

Conditions
Schizophrenia
Interventions
DRUG

AMG 747

Three dose levels once-daily oral administration

DRUG

Placebo

Once-daily oral administration

Trial Locations (38)

1309

Research Site, Takapuna, Auckland

3004

Research Site, Melbourne

5065

Research Site, Glenside

6010

Research Site, Mount Claremont

11004

Research Site, Glen Oaks

14618

Research Site, Rochester

20016

Research Site, Washington D.C.

27603

Research Site, Raleigh

28009

Research Site, Madrid

30308

Research Site, Atlanta

33161

Research Site, North Miami

39008

Research Site, Santander

45417

Research Site, Dayton

46010

Research Site, Valencia

60640

Research Site, Chicago

77008

Research Site, Houston

90073

Research Site, Los Angeles

90230

Research Site, Culver City

90502

Research Site, Torrance

90650

Research Site, Norwalk

90703

Research Site, Cerritos

92408

Research Site, San Bernardino

92804

Research Site, Anaheim

92845

Research Site, Garden Grove

107076

Research Site, Moscow

115552

Research Site, Moscow

141371

Research Site, Khot'kovo

192019

Research Site, Saint Petersburg

410028

Research Site, Saratov

539747

Research Site, Singapore

08053

Research Site, Marlton

T2N 4Z6

Research Site, Calgary

V2A 4M4

Research Site, Penticton

K7L 4X3

Research Site, Kingston

H3A 1A1

Research Site, Montreal

08036

Research Site, Barcelona

08940

Research Site, Cornellà de Llobregat

08907

Research Site, L'Hospitalet de Llobregat

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Amgen

INDUSTRY

NCT01568216 - 20101299: Study to Evaluate the Effect of AMG 747 on Schizophrenia Negative Symptoms | Biotech Hunter | Biotech Hunter